NDA 214801 · Taiho Oncology
Lytgobi
Futibatinib · Oral · Kinase Inhibitor
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanCDER novel approval, Sep 30, 2022: To treat intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Sep 30, 2022
Approved uses
1
Original approval plus efficacy supplements
Registered trials
24
6 Phase 3, 10 recruiting
FAERS reports
222
152 serious, 42 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 4, 2026.
LYTGOBI is indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements [see Dosage and Administration (2.1) ] . This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). LYTGOBI is a kinase inhibitor indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. ( 1 , 2.1 ) This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1 )
Mechanism: Futibatinib is a small molecule kinase inhibitor of FGFR 1, 2, 3, and 4 with IC 50 values of less than 4 nM. Futibatinib covalently binds FGFR. Constitutive FGFR signaling can support the proliferation and survival of malignant cells. Futibatinib inhibited FGFR phosphorylation and downstream signaling and decreased cell viability in cancer cell lines with FGFR alterations including FGFR fusions/rearrangements, amplifications, and mutations. Futibatinib demonstrated anti-tumor activity in mouse and rat xenograft models of human tumors with activating FGFR genetic alterations.
Therapeutic areas: Oncology · Gastroenterology and liver
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 30, 2022 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLetterLabelReview
2 products under this application
- LYTGOBI · FUTIBATINIB 16MG · TABLET, ORAL · Discontinued
- LYTGOBI · FUTIBATINIB 4MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Futibatinib" as an intervention, any sponsor and status, largest first.
American Society of Clinical OncologyAcademic, hospital or other
NCT02693535 · 4,200 participants (planned) · Start Mar 14, 2016 · Primary completion Dec 31, 2027
Drug: Sunitinib (CLOSED TO ENROLLMENT); Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT) and 10 more · For: Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors
Sites: Birmingham, Alabama; Phoenix, Arizona; Auburn, California · 181 sites in all
- A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)Recruiting
Vall d'Hebron Institute of OncologyAcademic, hospital or other
NCT03767075 · 1,000 participants (planned) · Start Dec 10, 2018 · Primary completion May 2027
Drug: Atezolizumab; Futibatinib and 1 more · For: Advanced Solid Tumor
Sites: Villejuif, France; Heidelberg, Germany; Dresden, Germany · 8 sites in all
- Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract CancerPivotal-lookingNot yet recruiting
UNICANCERAcademic, hospital or other
NCT07745296 · 990 participants (planned) · Start Jan 2, 2027 · Primary completion Jul 2, 2033
Drug: Futibatinib; Ivosidenib + Capecitabine and 2 more · For: Biliary Tract Cancer (BTC)
- AB122 Platform StudyRecruiting
Taiho Pharmaceutical Co., Ltd.Industry
NCT04999761 · 917 participants (planned) · Start Jun 1, 2021 · Primary completion Jun 2027
Drug: AB122; AB122 and 19 more · For: Advanced or Metastatic Solid Tumor; Pancreatic Ductal Adenocarcinoma; Colorectal Cancer and 6 more
Sites: Aichi, Japan; Chiba, Japan; Ehime, Japan · 9 sites in all
- Personalized Medicine for Advanced Biliary Cancer PatientsPivotal-lookingRecruiting
UNICANCERAcademic, hospital or other
NCT05615818 · 800 participants (planned) · Start Jul 18, 2024 · Primary completion Jun 2027
Drug: Futibatinib; Ivosidenib and 8 more · For: Biliary Tract Neoplasms
Sites: Brussels, Belgium; Edegem, Belgium; Leuven, Belgium · 69 sites in all
- Futibatinib (TAS-120) in Patients With Advanced Biliary Tract CancerPivotal-lookingRecruiting
Taiho Pharmaceutical Co., Ltd.Industry
NCT07710885 · 784 participants (planned) · Start Jun 24, 2026 · Primary completion Apr 30, 2030
Drug: Futibatinib; Zimberelimab and 4 more · For: Biliary Tract Cancer
Sites: Brisbane, Australia; Melbourne, Australia; Perth, Australia · 21 sites in all
- Molecular Profiling of Advanced Soft-tissue SarcomasPivotal-lookingCompleted
Institut National de la Santé Et de la Recherche Médicale, FranceGovernment (non-federal)
NCT03784014 · 603 participants · Start Oct 19, 2019 · Primary completion Dec 1, 2023
Drug: Nilotinib; Ceritinib and 6 more · For: Soft Tissue Sarcoma
Sites: Bordeaux, France; Dijon, France; Lille, France · 17 sites in all
Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
NCT02813135 · 472 participants (planned) · Start Aug 3, 2016 · Primary completion Feb 2031
Drug: Ribociclib; Topotecan and 22 more · For: Pediatric Cancer
Sites: Copenhagen, Denmark; Villejuif, France; Angers, France · 23 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea39
- hyperphosphataemia36
- death32
- disease progression31
- fatigue28
- nausea26
- dry mouth24
- off label use20
- vomiting18
- onychomadesis17
- blood phosphorus increased16
- constipation16
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 3 |
| 2022 | 14 |
| 2023 | 50 |
| 2024 | 59 |
| 2025 | 57 |
| 2026 | 39 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lytgobi (Futibatinib)
2024 spending
$21.8M
Beneficiaries
215
952 claims
Per beneficiary
$101,558
$195.00 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $7,249,603 |
| 2024 | $21,835,060 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
Goyal L, Meric-Bernstam F, Hollebecque A, et al. · N Engl J Med 2023 · Clinical Trial, Phase II, Multicenter Study
- Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study.
Meric-Bernstam F, Bahleda R, Hierro C, et al. · Cancer Discov 2022 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Evaluation of the Mass Balance and Metabolic Profile of Futibatinib in Healthy Participants.
Yamamiya I, Hunt A, Yamashita F, et al. · Clin Pharmacol Drug Dev 2023 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- A phase I drug-drug interaction study to assess the effect of futibatinib on P-gp and BCRP substrates and of P-gp inhibition on the pharmacokinetics of futibatinib.
Long A, Yamamiya I, Valentine M, et al. · Clin Transl Sci 2024 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Evaluation of Potential Food Effects and Drug Interactions With Lansoprazole in Healthy Adult Volunteers Receiving Futibatinib.
Yamamiya I, Hunt A, Yamashita F, et al. · Clin Pharmacol Drug Dev 2023 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Effect of Futibatinib on Cardiac Repolarization: Results of a Randomized, Controlled, Double-Blind, QT/QTc, Phase 1 Study in Healthy Subjects.
Yamamiya I, Lester R, Sonnichsen D, et al. · Clin Pharmacol Drug Dev 2023 · Randomized Controlled Trial, Clinical Trial, Phase I
Sponsor: Taiho Oncology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.